Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482934 | 0.81 | L3MBTL1 (0.42) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL22918113 | 0.79 | KDM1A (0.39) | ALDH1A1MAOBSLC6A4 | |
| SCHEMBL12804885 | 0.77 | ALPG (0.47) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL451750 | 0.77 | MAPT (0.46) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL2277113 | 0.77 | MAOB (0.55) | MAPTL3MBTL1LMNAMAOBLTA4H | |
| SCHEMBL451300 | 0.76 | SIGMAR1 (0.45) | MAPTL3MBTL1ALDH1A1OPRM1KDM4E | |
| SCHEMBL17106559 | 0.75 | PDE4B (0.48) | MAPTALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL6211633 | 0.73 | MAOB (0.55) | MAPTL3MBTL1ALDH1A1LMNAMAOB | |
| SCHEMBL17106580 | 0.73 | KMT2A (0.47) | MAPTSGMS2ALDH1A1HTR1A | |
| SCHEMBL435851 | 0.73 | MAPT (0.49) | MAPTMAPK1TDP1L3MBTL1ALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445714-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8372883-B2 | Methods of using cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8338632-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263888-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263877-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2066329-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | Reviva Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | AADAC, PNMT, INMT | MAPT 4201/4885MAPK1 4721/4885TDP1 3578/4885 |
| US-20110263888-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | MAPT 4230/4885MAPK1 4771/4885TDP1 3922/4885 |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | MAPT 4240/4885MAPK1 4684/4885TDP1 3924/4885 |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | AADAC, GPR119, MC4R | MAPT 4089/4885MAPK1 4812/4885TDP1 4167/4885 |
| US-20110263877-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | MAPT 4230/4885MAPK1 4771/4885TDP1 3922/4885 |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | MAPT 4240/4885MAPK1 4684/4885TDP1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.